These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22081368)

  • 1. Promise of factor Xa inhibition in acute coronary syndromes.
    Lee L; Chew D
    Curr Cardiol Rep; 2012 Feb; 14(1):40-8. PubMed ID: 22081368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor Xa inhibitors for acute coronary syndromes.
    Brito V; Ciapponi A; Kwong J
    Cochrane Database Syst Rev; 2011 Jan; (1):CD007038. PubMed ID: 21249686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of acute coronary syndromes with fondaparinux.
    Wienbergen H; Zeymer U
    Vasc Health Risk Manag; 2007; 3(3):321-9. PubMed ID: 17703640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of anticoagulation in acute coronary syndromes.
    Latour-Pérez J; de-Miguel-Balsa E
    Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inactivation in acute coronary syndrome.
    Barantke M; Bonnemeier H
    Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Factor Xa : a potential target for the development of new anticoagulants.
    Alexander JH; Singh KP
    Am J Cardiovasc Drugs; 2005; 5(5):279-90. PubMed ID: 16156684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux in Acute Coronary Syndromes.
    Trailokya A; Dhall A; Kumbla DK
    J Assoc Physicians India; 2015 Jul; 63(7):83-7. PubMed ID: 26731838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and experimental experience with factor Xa inhibitors.
    Viles-Gonzalez JF; Gaztanaga J; Zafar UM; Fuster V; Badimon JJ
    Am J Cardiovasc Drugs; 2004; 4(6):379-84. PubMed ID: 15554723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Factor Xa-inhibition in interventional cardiology].
    Ahrens I; Peter K; Bode C
    Hamostaseologie; 2007 Dec; 27(5):328-32. PubMed ID: 18060241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G; Mehta SR; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
    Yong CM; Boyle AJ
    Curr Vasc Pharmacol; 2010 Jan; 8(1):5-11. PubMed ID: 19485937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications.
    McCann CJ; Menown IB
    Vasc Health Risk Manag; 2008; 4(2):305-13. PubMed ID: 18561506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
    Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS;
    JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fondaparinux in acute coronary syndromes.
    Chaturvedi V; Karthikeyan G
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1615-23. PubMed ID: 19929450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis.
    Kalicki RM; Aregger F; Alberio L; Lämmle B; Frey FJ; Uehlinger DE
    Thromb Haemost; 2007 Dec; 98(6):1200-7. PubMed ID: 18064314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.
    Burke DA; Warraich HJ; Pinto DS
    Curr Cardiol Rep; 2012 Aug; 14(4):493-501. PubMed ID: 22661270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG
    Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.